Replies to post #813746 on NorthWest Biotherapeutics Inc (NWBO)

[Investor082]

“How many shareholders on the dark day of October 5, 2020 would have predicted that we would still be debating this kind of crap and would still be a pre-revenue biotech valued as less than 50 cents a share in Q1 2026.”

—It’s a reflection of a dilution scam. Get out with whatever you can salvage and invest in a well run company with solid management team that has a consistent history of providing shareholder return over the years. The minions will continue to dangle carrots to trap the bag holders and make grandiose projections so that LP and her financiers can continue to dump shares, but the reality is the following:

1) No FDA BLA submission
2) No NICE evidence submission
3) No big pharma partnership
4) No institutional ownership

5.5 years since data lock and counting. Look at SGEN as a template for how successful biotech is built.

[RRP60]

HL, i agree, none of us thought we will be like this in oct 2020, when we got the data lock. I was optimistic , we will be in hundred dollars price range in five years if we succeed in the trial. The interim trial results at that time were very encouraging  for me and i jumped into this investment thinking its going to be a slamdunk investment in due course.The time line is not going as we anticipated. Thats all. but the drug is still very good and moved past many checks and the company is trying its best to straighten the manufacturing issues. If MHRA is acting irresponsibly and dragging its feet, we cannot completely blame nwbo for it. I hope they have their own good reasons for it.  Moreover, nobody has the ability to predict future. So please wait for the result if you have the patience and energy. It has become an individual decision at this point about how to deal with this investment. This is just my opinion only. 

[barnstormer]

Happy, your response reminded me that the MHRA's funding is provided for the most part by pharmaceutical companies, so if I put on my cynical (realist) hat, it's a possibility that one or more of the BPs could imply it may withhold or delay funding based on approval. I'm also reminded of a story on how bureaucracies can delay on sidetrack the process. In that case the story was that when A got a request, he filed it. Held until he got a follow-up, dropped it in a second folder. Held until received a second request, dropped in a 3rd folder. When a third request was received, forwarded it to the next person up the line.